Ox-1 Investor Presentation
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your TCF notes
Alderley Park, 10 June 2025 - TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on neuropsychiatry and oncology, will be hosting a webinar for investors at 11.30am BST, on Wednesday 11 June 2025.
It will provide an in-depth look at the Ox-1 addiction programme. The session will be led by TheraCryf's CBO, Dr Helen Kuhlman, together with neuroscientist and consultant to the Company, Dr Fraser Murray. Access to the session is open to all existing and potential shareholders via the Investor Meet Company platform.
Investors who already follow TheraCryf plc on the Investor Meet Company platform have automatically been invited. New registrants can sign up to Investor Meet Company for free HERE.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.